You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SUPERCONDUCTING MAGNET FOR MICROCOIL NMR

    SBC: American Magnetics, Inc.            Topic: N/A

    DESCRIPTION (Verbatim from the Applicant's Abstract): The specific aims of this Phase I STTR project, proposed by the American Magnetics, Inc. in partnership with the MIT Francis Bitter Magnet Laboratory, are: 1) experimental demonstration of feasibility of innovative design and operation features applicable to NMR Nb3Sn-magnet/cryocooler systems; and 2) co ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  2. Gene Expression and Diagnosis of Autoimmune Disease

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by the applicant): Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, type I diabetes, and multiple sclerosis, are thought to arise from abnormalities of innate or adaptive immune responses. Autoimmune diseases are often difficult to diagnose, as the symptoms can be typical of other conditions and quite vague, such as musculoskeletal complaints ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  3. Gene Expression and Diagnosis of Autoimmune Disease

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Autoimmune diseases are thought to arise from abnormalities in innate or adaptive immune responses and most likely have both genetic and environmental components. Diagnosis of autoimmune disease is often difficult, as t he symptoms can be relatively nonspecific. Furthermore, no available blood test can accurately exclude the possibility of an autoimmune disease ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Gene Expression and Diagnosis of Diabetes

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be typical of other conditions and quite vague. No currently available blood test accurately excludes or includes the possibility of an autoimmune disease in a subject, and a battery of tests and a period of observation are usually required. A single test that could readily distinguish between ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  5. Gene Expression and Diagnosis of Diabetes

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be nonspecific. A single test that could readily distinguish between an autoimmune and non-autoimmune disorder would allow physicians to focus efforts on the specific disease that affects the patient. This is critical for diabetes mellitus (DM), which has two subsets, Type I and Type II. The sub ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Point Source Ozonation to Minimize Antibiotic Resistance

    SBC: Biodetection Instruments, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): BluelnGreen, LLC proposes to develop an effective, versatile and cost efficient device for the application of ozone micro-bubbles to the effluent of critical point sources of medical wastewater (hospitals, large clinics and pharmaceutical manufacturing plants) to reduce the overall amount of both antibiotic residuals and resistant pathogens that are released t ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Point Source Ozonation to Minimize Antibiotic Resistance

    SBC: Biodetection Instruments, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): In this Phase II project, BlueInGreen, LLC will build a hypersaturated dissolved ozone (HYDOZTM) unit to deploy in a large pilot-scale study at Springdale Wastewater Treatment Facility (SWWTF) in Springdale, Arkansas. F urthermore, BlueInGreen will collaborate with the University of Arkansas to measure the ability of HYDOZ ozonation to remove refractory microbe ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Antiatherogenic Properties of tert-Butylhydroquinone

    SBC: BIOINVENTIONS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and tri ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  9. TGF-beta for Pleurodesis

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 50,000 cancer patients a year have recurrent fluid accumulation in the space between their chest wall and lung. This condition is called malignant pleural effusion (MPE). This fluid impairs breathing and worsens the quality of life in these patients. The current treatments are not ideal and include removing the fluid by repetitive needle aspiratio ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  10. High Purity Amphotericin B: A Safer Antimycotic in AIDS

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cumberland Pharmaceuticals and the University of Mississippi Mycotic Research Centers' long-term goal will be to improve anti-fungal pharmacotherapy particularly for patients with human immunodeficiency infections (HIV). We are jointly developing a high purity amphotericin B (AmB HP) product for intravenous administration. The nominal purity of AmB HP is 95%; ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government